Quotables
"The abolishment of pain in surgery is a chimera. It is absurd to go on seeking it...knife and pain are two words in surgery that must forever be associated in the consciousness of the patient."
Dr. Alfred Velpeau, French surgeon ; 1839
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8183288 | Amino acid compounds A method for increasing the bioabsorption of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an am... | 05/22/2012 |
| 8114909 | Treating or preventing restless legs syndrome using prodrugs of GABA analogs Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or p... | 02/14/2012 |
| 8101661 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same Disclosed are polar, hydrophilic stimulant prodrug compositions comprising at least one stimulant chemically attached to a polar hydrophilic ligand, a salt thereof, a derivative thereof, or a combination thereof. Also disclosed are non-standard amino acid conjugates... | 01/24/2012 |
| 8067471 | Composition comprising free amino acids A composition is described that can be used in prevention or treatment of patients having impaired gastro-intestinal tract function. The composition comprises free amino acids including about 9.0% to about 17.0% glutamic acid. Methods of treatment of impaired gastro... | 11/29/2011 |
| 8048923 | Treatment of polyglutamine disorders caused by expanding genomic CAG nucleotides The present invention relates to the treatment or prevention of neurodegenerative polyglutamine diseases by the administration of effective amounts of L-methionine S-sulfoximine, L-ethionine S-sulfoximine, glufosinate and/or branched chain α-keto acids. In particul... | 11/01/2011 |
| 7999007 | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reduc... | 08/16/2011 |
| 7973077 | Amino acid based compositions for the treatment of pathological conditions distinguised by insufficient mitochondrial function The present invention relates to compositions suitable for the treatment of pathological conditions distinguished by insufficient or reduced mitochondrial function. The compositions comprise, as principal active ingredients, the amino acids leucine, isoleucine and v... | 07/05/2011 |
| 7947738 | Bicyclic γ-amino acid derivative It is intended to provide a bicyclic γ-amino acid derivative having excellent activity as an α2δ ligand. The present invention provides a compound represented by the general formula (I): wherein R1,... | 05/24/2011 |
| 7939563 | Remedy for hypertension Provided is a method of treating hypertension, which comprises administering an effective amount of a compound represented by the following formula (1) or (2): wherein, R1 and R2 are the same or differ... | 05/10/2011 |
| 7932287 | Therapeutic compositions and uses The invention provides compositions for and methods of treating a number of disorders. In one embodiment, the invention provides a method of treating a wide range of conditions by administering to a human being in need of such treatment, a therapeutically effective ... | 04/26/2011 |
| 7858663 | Physical and chemical properties of thyroid hormone organic acid addition salts A pharmaceutical composition comprising the salt of a thyroid hormone selected from the group consisting of levothyroxine and liothyronine and an organic acid comprising at least one aromatic ring having at least one hydroxyl moiety and at least one carboxylic acid ... | 12/28/2010 |
| RE41920 | Isobutylgaba and its derivatives for the treatment of pain The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy. ... | 11/09/2010 |
| 7795309 | Topical formulation including diclofenac, or a pharmaceutically acceptable salt thereof There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected ... | 09/14/2010 |
| 7786168 | Phenolic acid salts of gabapentin in solid dosage forms and methods of use The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained... | 08/31/2010 |
| 7781486 | Punctual stimulation therapy The invention relates to the use of a sterile aqueous solution of a substance inhibiting the enzymatic decomposition of endogenous opioide neuropeptides, especially enkephalins, for producing a preparation provided for intravenous infusion, in order to intensify the... | 08/24/2010 |
| 7776917 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same Disclosed are amphetamine prodrug compositions comprising at least one non-standard amino acid conjugate of amphetamine, a salt thereof, a derivative thereof, or a combination thereof. Methods of making and using the same are also disclosed. ... | 08/17/2010 |
| 7750046 | Treatment of symptoms associated with irritable bowel syndrome Methods are provided for use in treating humans suffering from irritable bowel syndrome. In the subject methods, an effective amount of a nerve-acting agent, e.g., lidocaine, topiramate, mexiletine and gabapentin, etc., is administered to a human suffering from irri... | 07/06/2010 |
| 7737180 | Use of neboglamine (CR 2249) as an antipsychotic and neuroprotective Use of neboglamine, (S)-4-amino-N-(4,4-dimethylcyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), of the racemate thereof or of a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of schizophrenia. ... | 06/15/2010 |
| 7737179 | Methods for treatment of dermatological conditions A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed. ... | 06/15/2010 |
| 7728037 | Alpha-ketoglutarates of active ingredients and compositions containing same Novel stable and pharmacologically acceptable salts of L-carnitine and lower alkanoyl L-carnitines with alpha-ketoglutaric acid are disclosed as well as the compositions useful as dietary and dietetic supplements, nutraceuticals or drugs containing same. ... | 06/01/2010 |
| 7709529 | Treatment of cancer with glutamine Provided are methods of treating cancer, and/or the side effects of cancer therapy, involving the administration of glutamine, optionally in combination with a carbohydrate carrier that enhances the absorption of glutamine. ... | 05/04/2010 |
| 7700652 | Treating urinary incontinence using prodrugs of GABA analogs Disclosed herein are methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat and/or prevent urinary incontinence in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating and/or preventing urinary in... | 04/20/2010 |
| 7662856 | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine Antimycorbacterial compositions are disclosed comprising at least one hydroxamate or at least one hydroxamate and at least one hydroxylamine. The preferred ratio of hydroxamate to hydroxylamines is about 100:1 to about 1:1. A method for inhibiting mycobacterial grow... | 02/16/2010 |
| 7645796 | Amino acid composition promoting collagen synthesis Herein are disclosed an excellent collagen synthesis-promoting amino acid composition that are characterized by containing specific amino acids at a specific ratio, more specifically, by containing 10-40 parts by weight of L-arginine and/or 10-40 parts by weight of ... | 01/12/2010 |
| 7635717 | Process for the preparation of amino methyl cyclo alkane acetic acids This invention relates to an improved process for the preparation of amino methyl cyclo alkane acetic acids. This invention particularly relates to an improved process for the preparation of gabapentin (which is chemically known as 1-aminomethyl-1-cyclohexaneacetic ... | 12/22/2009 |
| 7632864 | Gabapentin analogues and process thereof The present invention relates to compounds trans (E) and cis (Z) stereoisomers of 4-t-butyl gabapentin of formula (11) and (12) and a process for the preparation of the said stereoisomers. ... | 12/15/2009 |
| 7612112 | Methods of treatment using a gastric retained gabapentin dosage A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. ... | 11/03/2009 |
| 7608640 | Glycine betaine and its use The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation. ... | 10/27/2009 |
| 7592371 | External preparation It is an object of the present invention to provide an external preparation having enhanced transdermal penetration of a mast cell degranulation inhibitor. It is also an object of the present invention to provide a method for improving the photostability of a prepar... | 09/22/2009 |
| 7544715 | Tumor imaging compounds The invention provides novel amino acid compounds of use in detecting and evaluating brain and body tumors. These compounds combine the advantageous properties of α-aminoisobutyric acid (AIB) analogs namely, their rapid uptake and prolonged retention in tumors with... | 06/09/2009 |
| 7534818 | Method of reducing alopecia and bladder toxicity of cyclophosphamide The present invention discloses a method for reducing alopecia and bladder toxicity associated with the anti-cancer agent cyclophosphamide. The method comprises administering to an individual, in need of such a treatment, cyclophosphamide and a selenium compound. Th... | 05/19/2009 |
| 7517909 | Amino acids with affinity for the α2δ-protein This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders. ... | 04/14/2009 |
| 7498292 | Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to methods for identifying autoinduc... | 03/03/2009 |
| 7488755 | Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid The use of R(+)-2-amino-3-hydroxypropanoic acid derivatives, nitrogen substituted by a (C1-C6)alkyl, (C3-C6)alkenyl, 3-oxo(C5-C6)alkyl, 3-oxo(C4-C6)alken-2-yl, phenyl(C1 | 02/10/2009 |
| 7456216 | Methods for the preparation and formulation of l-carnitine valproate salts The present invention relates to methods for preparing an L-carnitine valproate salt and administering this compound to a subject in need of treatment with valproate. Pharmaceutical compositions are also provided that are useful therapies for the treatment of neurol... | 11/25/2008 |
| 7432299 | Method of treatment for sexual dysfunction Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation. ... | 10/07/2008 |
| 7429673 | TRPV1 agonists, formulations containing them and uses thereof The compounds of the general formula (I) in which X is represents two hydrogen atoms, a π-bond, oxygen or methylene: R2 is a C6-C12 aryl, or arylalkyl residue: R3 is hydrogen, 2-hydroxyethyl or 2-aminoethyl are useful for the treatment of path... | 09/30/2008 |
| 7427619 | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy Pharmaceutical compositions effective in alleviating or reducing the effects of fatigue and weakness associated with cancer and cancer chemotherapy are disclosed. The pharmaceutical compositions of the present invention comprise riboflavin, effectors of the urea cyc... | 09/23/2008 |
| 7425649 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia. ... | 09/16/2008 |
| 7419981 | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. A par... | 09/02/2008 |
